| アブストラクト | BACKGROUND: Immune checkpoint inhibitor (ICI) therapy combined with conventional therapies is being broadly applied in non-small cell lung cancer (NSCLC) patients. However, the risk of interstitial pneumonitis (IP) following a combined regimen is incompletely characterized. METHODS: A total of 46,127 NSCLC patients were extracted for disproportionality analyses of IP from the Food and Drug Administration's Adverse Event Reporting System (FAERS) database. A total of 1108 NSCLC patients who received ICI treatment at Nanfang Hospital of Southern Medical University were collected and utilized for real-world validation. RESULTS: Of the 46,127 patients with NSCLC, 3830 cases (8.3%; 95% confidence interval [CI], 8.05-8.56) developed IP. Multivariable logistic regression analyses revealed that the adjusted ROR of ICI combined with radiation (RT) was the highest (121.69; 95% CI, 83.60-184.96; P < 0.0001) among all therapies, while that of ICI combined with chemotherapy (CHEMO) or targeted therapy (TARGET) was 0.90 (95% CI, 0.78-1.04; P = 0.160) and 1.49 (95% CI, 0.95-2.23; P = 0.065), respectively, using ICI monotherapy as reference. Furthermore, analyses from our validation cohort of 1108 cases showed that the adjusted odds ratio of ICI combined with RT was the highest (12.25; 95% CI, 3.34-50.22; P < 0.01) among all the therapies, while that of ICI combined with CHEMO or TARGET was 2.32 (95% CI, 0.89-7.92; P = 0.12) and 0.66 (95% CI, 0.03-4.55; P = 0.71), respectively, using ICI monotherapy as reference. CONCLUSIONS: Compared with ICI monotherapy, ICI combined with RT, rather than with CHEMO or TARGET, is associated with a higher risk of IP in NSCLC patients. Hence, patients receiving these treatments should be carefully monitored for IP. |
|---|
| ジャーナル名 | BMC medicine |
|---|
| Pubmed追加日 | 2023/1/5 |
|---|
| 投稿者 | Guo, Xue-Jun; Cai, Xiao-Ting; Rong, Zi-Xuan; Zhang, Yan-Pei; Wen, Yu-Xiang; Bai, Xue; Wang, Jian; Fu, Qiang John; Guo, Ze-Qin; Long, Li-Li; Ma, Si-Cong; Tang, Xin-Ran; Liu, Li; Guan, Jian; Dong, Zhong-Yi; Wu, De-Hua |
|---|
| 組織名 | Department of Radiation Oncology, Nanfang Hospital, Southern Medical University,;1838 North Guangzhou Avenue, Guangzhou, 510515, China.;Department of Community Health, School of Arts and Sciences, Tufts University,;Medford, MA, USA.;Information Management and Big Data Center, Nanfang Hospital, Southern Medical;University, Guangzhou, China.;1838 North Guangzhou Avenue, Guangzhou, 510515, China. guanjian5461@163.com.;1838 North Guangzhou Avenue, Guangzhou, 510515, China. dongzy1317@foxmail.com.;1838 North Guangzhou Avenue, Guangzhou, 510515, China. 18602062748@163.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36600276/ |
|---|
